Brokerages Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $13.25.

A number of research analysts have commented on the company. Chardan Capital reaffirmed a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a report on Wednesday, June 18th. Needham & Company LLC reissued a "buy" rating and set a $9.00 target price on shares of Immuneering in a report on Wednesday, June 18th. Oppenheimer reduced their target price on Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Mizuho increased their target price on Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Wednesday, June 18th.

Immuneering Stock Up 2.3%

IMRX traded up $0.09 during trading on Wednesday, reaching $4.05. 334,937 shares of the company's stock were exchanged, compared to its average volume of 1,369,137. The company has a market capitalization of $145.74 million, a P/E ratio of -2.07 and a beta of 0.38. The business has a 50 day moving average price of $2.46 and a 200 day moving average price of $1.95. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $4.60.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). As a group, research analysts forecast that Immuneering will post -1.86 EPS for the current year.

Insider Buying and Selling at Immuneering

In related news, Director Thomas J. Schall acquired 40,485 shares of the stock in a transaction dated Tuesday, June 17th. The stock was bought at an average cost of $2.21 per share, for a total transaction of $89,471.85. Following the completion of the transaction, the director directly owned 43,385 shares of the company's stock, valued at $95,880.85. The trade was a 1,396.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Peter Feinberg acquired 25,000 shares of Immuneering stock in a transaction on Wednesday, June 18th. The stock was purchased at an average cost of $2.53 per share, with a total value of $63,250.00. Following the purchase, the director directly owned 136,766 shares of the company's stock, valued at approximately $346,017.98. This trade represents a 22.37% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders bought 127,507 shares of company stock worth $334,318. 22.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Immuneering

A number of hedge funds and other institutional investors have recently modified their holdings of IMRX. Southport Management L.L.C. raised its position in shares of Immuneering by 4.9% in the 4th quarter. Southport Management L.L.C. now owns 215,000 shares of the company's stock worth $473,000 after acquiring an additional 10,000 shares in the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Immuneering in the fourth quarter worth about $390,000. HighTower Advisors LLC increased its stake in Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company's stock worth $128,000 after acquiring an additional 12,600 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of Immuneering by 77.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after purchasing an additional 22,400 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock worth $111,000 after buying an additional 10,126 shares during the period. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.